However, the strategies attempting to reactivate CD8+ T cells tend to have possible drug toxicities and high costs, and targeting CD8+ T cells alone does not provide enough efficacy for successful cancer treatment considering the complexity of the immunosuppressive microenvironment (9, 60). This evidence concerns the gene CD8A and cancer.